SCHEMBL3538530

SCHEMBL3538530

CCOC(=O)C(CC(C)=O)C(=O)CC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.41
LMNA P02545 2/20 0.41
HSD17B10 Q99714 1/20 0.41
SOAT1 P35610 1/20 0.39
TDP1 Q9NUW8 5/20 0.36
GAA P10253 2/20 0.34
ALOX15 P16050 1/20 0.34
MGAM O43451 1/20 0.34
SI P14410 1/20 0.34
MGAM2 Q2M2H8 1/20 0.34
KMT2A Q03164 3/20 0.34
HPGD P15428 3/20 0.34
MEN1 O00255 2/20 0.34
NPC1 O15118 1/20 0.33
RECQL P46063 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MMP8 P22894 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2097011 0.87 ALDH1A1 (0.48) ALDH1A1LMNAHSD17B10SOAT1TDP1
SCHEMBL4529653 0.83 MGAM (0.44) ALDH1A1LMNAHSD17B10SOAT1TDP1
SCHEMBL8577401 0.83 ALDH1A1 (0.44) ALDH1A1LMNAHSD17B10SOAT1TDP1
SCHEMBL5001158 0.83 ALDH1A1 (0.44) ALDH1A1LMNAHSD17B10SOAT1TDP1
SCHEMBL3142804 0.80 SOAT1 (0.44) ALDH1A1LMNAHSD17B10SOAT1TDP1
SCHEMBL24834180 0.78 ALDH1A1 (0.43) ALDH1A1TDP1
SCHEMBL10611181 0.77 SOAT1 (0.41) ALDH1A1LMNAHSD17B10SOAT1TDP1
SCHEMBL27617570 0.75 SOAT1 (0.39) ALDH1A1LMNAHSD17B10SOAT1TDP1
SCHEMBL22591704 0.75 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10TDP1KMT2A
SCHEMBL5755181 0.75 ALDH1A1 (0.37) ALDH1A1LMNAHSD17B10SOAT1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7829586-B2 Aryl-substituted nitrogen-containing heterocyclic compounds BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-11-09 US disclosed
US-20090275617-A1 Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds MSD K.K. (JP) 2009-11-05 US disclosed
CN-101277932-A Aryl-substituted nitrogen-containing heterocyclic compound BANYU PHARMA CO LTD (JP) 2008-10-01 CN disclosed
EP-1935881-A1 ARYL-SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275617-A1 Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds OPRL1, NPSR1, NPBWR1 ALDH1A1 1623/4885LMNA 3162/4885HSD17B10 2264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.